مقالات پذیرفته شده در نهمین کنگره بین المللی زیست پزشکی
Pharmacogenetic Profile of Common Polymorphisms in Iranian ALL Patients and Their Association with Treatment Response
Pharmacogenetic Profile of Common Polymorphisms in Iranian ALL Patients and Their Association with Treatment Response
Majid Mesgar Tehrani,1,*Kosar Taheri,2Mohammad Mahdi Eslami,3Reza Mirlohi,4
1. Member of the Core Committee of the National Genomics Hub, Shahid Beheshti University of Medical Sciences, Tehran, Iran 2. Alzahra University 3. Member of the Bioinformatics Research Group, Nasim Research Institute, Tehran, Iran 4. Member of the Bioinformatics Research Group, Nasim Research Institute, Tehran, Iran
Introduction: Single nucleotide polymorphisms (SNPs) are important for the study of human disease. SNPs play a role in Acute Lymphoblastic Leukemia (ALL) susceptibility are linked to various pathogenic phenotypes and can affect genetically mediated drug toxicity.
Methods: The NCBI dbSNP database was used to identify SNPs associated with ALL and other phenotypes. These were analyzed using the pharmacogenetic software MegaGene to detect potential drug side effects with a genetic basis.
Results: The most frequent SNPs in order were CEBPE (rs2239633), CDKN2B (rs3217992), and IL7R (rs6897932). IL7R is associated with blood pressure under Dasatinib treatment.
Conclusion: Some chemotherapy drugs in Iran may have genetically based side effects. Physicians are advised to sequence common SNPs before prescribing to identify risks and choose drugs with fewer side effects.